Kinoshita K, Mitani A, Hearse D J, Braimbridge M V, Manning A S
Department of Cardiovascular Surgery, Kyushu University School of Medicine, Fukuoka, Japan.
J Surg Res. 1989 Aug;47(2):166-72. doi: 10.1016/0022-4804(89)90083-8.
The effects of three calcium antagonists (diltiazem, verapamil, and nifedipine) on reperfusion-induced arrhythmias were compared in a conscious rat preparation with coronary artery occlusion and implanted electrocardiogram limb electrodes. Upon reperfusion after a 5-min period of occlusion, all (15/15) untreated control rats exhibited immediate ventricular tachycardia, which rapidly deteriorated to ventricular fibrillation; 87% (13/15) of the rats died as a consequence of these rhythm disturbances. In the groups treated with calcium antagonists, each drug (diltiazem, verapamil, or nifedipine) was given as an intravenous bolus 10 min prior to coronary occlusion (n = 12 in each group). The incidence of ventricular fibrillation was significantly reduced by all three calcium antagonists and this antifibrillatory effect resulted in a significantly lower mortality in all drug-treated groups. With diltiazem (0.5 and 2.0 mg/kg) mortality fell from 87 to 42% (P less than 0.05) and 35% (P less than 0.01), respectively; with verapamil (0.5 and 5.0 mg/kg) it fell to 25% (P less than 0.01) and 0% (P less than 0.001); and with nifedipine (5.0 and 50 micrograms/kg), it fell to 25% (P less than 0.01) and 8% (P less than 0.001). At a dose of 5.0 mg/kg, verapamil caused a large reduction in heart rate both prior to and during coronary occlusion and reperfusion; however, with other doses and drugs no significant changes in heart rate were observed. ST segment elevation during the 5-min ischemic period was reduced by pretreatment with all drugs. In conclusion, in the conscious rat, pretreatment with diltiazem, verapamil, or nifedipine affords some protection against reperfusion-induced arrhythmias.(ABSTRACT TRUNCATED AT 250 WORDS)
在清醒大鼠制备模型中,通过冠状动脉闭塞和植入心电图肢体电极,比较了三种钙拮抗剂(地尔硫䓬、维拉帕米和硝苯地平)对再灌注诱导的心律失常的影响。在5分钟闭塞期后的再灌注时,所有(15/15)未治疗的对照大鼠均立即出现室性心动过速,并迅速恶化为心室颤动;87%(13/15)的大鼠因这些节律紊乱而死亡。在接受钙拮抗剂治疗的组中,每种药物(地尔硫䓬、维拉帕米或硝苯地平)在冠状动脉闭塞前10分钟静脉推注给药(每组n = 12)。所有三种钙拮抗剂均显著降低了心室颤动的发生率,这种抗颤动作用导致所有药物治疗组的死亡率显著降低。地尔硫䓬(0.5和2.0 mg/kg)治疗后死亡率分别从87%降至42%(P < 0.05)和35%(P < 0.01);维拉帕米(0.5和5.0 mg/kg)治疗后死亡率降至25%(P < 0.01)和0%(P < 0.001);硝苯地平(5.0和50 μg/kg)治疗后死亡率降至25%(P < 0.01)和8%(P < 0.001)。在5.0 mg/kg剂量下,维拉帕米在冠状动脉闭塞和再灌注之前及期间均导致心率大幅降低;然而,使用其他剂量和药物时,未观察到心率有显著变化。所有药物预处理均降低了5分钟缺血期的ST段抬高。总之,在清醒大鼠中,地尔硫䓬、维拉帕米或硝苯地平预处理可对再灌注诱导的心律失常提供一定保护。(摘要截短至250字)